Biogen Alzheimer’s Drug Fails to Gain FDA Panel’s Backing

Bookmark
(Bloomberg) -- Biogen Inc.’s experimental Alzheimer’s disease therapy failed to gain support from a panel of U.S. Food and Drug Administration advisers on Friday, putting the drug at a crossroads a...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.